
Opinion|Videos|July 29, 2024
Limitations of NCCN PD-L1 Expression Recommendations
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How could emergingoverall survival data from trials like
POSEIDON andKEYNOTE-189 impact future treatment guidelines and our understanding of long-term outcomes?
- What evidence supports using dual checkpoint inhibitor therapy plus chemotherapy over chemotherapy alone in the first-line driver-negative setting?
Advertisement
Related to this article

The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.

A scoping review of 15 studies found psoriasis prevalence markedly lower across 13 indigenous populations worldwide.

A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.

A systemic sclerosis inception cohort and 17-study meta-analysis found a nearly 5-fold increase in lung cancer risk.

Medicare Advantage plans have varied motivations, strategies, and aspirations for addressing health-related social needs among home health beneficiaries, highlighting a need to expand the scope of supplemental benefits.

2026 Nobel Prize in Medicine honors optogenetics pioneers who turn algae light-sensing protein into neural switches, transforming brain mapping and enabling vision-restoration trials.

Medicare's Transforming Episode Accountability Model is projected to save $46.6 million by 2030, with safety-net hospitals potentially receiving the highest reconciliation payments.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
3
VBC Risk Is Outpacing Provider Readiness, CMS Must Act
4
FDA Approves First Heart Valve to Keep Pace With Children's Growth
5

